Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
BVBioventus Inc. logo

Bioventus Inc. (BVS)

NASDAQ · Currency in USD
$14.96 ▼ -0.08 (-0.53%)
At close: Oct 23, 4:00 PM ET. Market closed.
$14.98 ▲ +0.02 (+0.17%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$15.04
Open
$14.94
Day's Range
$14.80 – $15.09
52 Week Range
$6.47 – $15.89
Volume
386,497
Avg. Volume
617,860
Market Cap
$1.02B
Beta (5Y Monthly)
0.64
PE Ratio (TTM)
18.62
EPS (TTM)
$0.80
Earnings Date
Nov 3, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$18.33

Profile: Bioventus Inc.

Sector
Healthcare
Industry
Medical - Devices
Full-time employees
950
CEO
Robert Claypoole

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion.

Earnings

Next report: Tue, Nov 3, 2026
EPS estimate $0.15 · Revenue est. $149.51M
DateEst.Actual
Aug 5, 2026$0.22$0.22Beat
May 6, 2026$0.09$0.15Beat
Mar 5, 2026$0.22$0.24Beat
Nov 4, 2025$0.22$0.15Miss
Aug 6, 2025$0.22$0.21Miss
May 6, 2025$0.06$0.08Beat

Analyst view

Consensus price target
$18.33 ▲ +22.5%
Range $18.00 – $19.00
Rating: Buy
Buy 71% · Hold 29% · Sell 0%

Get free alerts on BVS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.